Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Uterine Myxoid Inflammatory Myofibroblastic Sarcoma (MIMS) Harboring Pathogenic KRAS Mutations and Expressing ER, PR, and CD10.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists - 1 Sept 2026

Xu Jin, Kushner David, Weisman Paul S

Abstract excerpt

Myxoid inflammatory myofibroblastic sarcoma (MIMS) is a recently described aggressive sarcoma with deceptively bland spindled cells with a myofibroblastic phenotype and myxoid stroma. These tumors are negative for ALK gene rearrangements, but have been shown to harbor gene fusions involving PDGFRA/B , JAK1 , and PML and/or mutations involving KRAS . Only one uterine case has been previously reported. Here we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Myofibroblasts
Share to Neprilysin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to Sarcoma

Share to Uterine Neoplasms

Share to Uterus

Source

Identifiers

PMID: 42206731
DOI: 10.1097/PGP.0000000000001192

Genes

ALK
KRAS
JAK1
PDGFRA
PML
ROS1
LATS1
PLAG1
RAD51B

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Uterine Myxoid Inflammatory Myofibroblastic Sarcoma (MIMS) Harboring Pathogenic KRAS Mutations and Expressing ER, PR, and CD10.PMID 42206731Read ↗

[Uterine inflammatory myofibroblastic tumor: a clinicopathological and molecular genetic analysis of eight cases].Semantic proximity Read ↗

Uterine Inflammatory Myofibroblastic Tumors Frequently Harbor ALK Fusions With IGFBP5 and THBS1Semantic proximity Read ↗

A Distinct Subtype of Uterine Sarcoma: Case Report of a High-Grade Uterine Sarcoma With Myogenic Differentiation Harboring a PDGFRB Hotspot Mutation.Semantic proximity Read ↗

High-Grade Sarcomas with Myogenic Differentiation Harboring Hotspot PDGFRB Mutations.Semantic proximity Read ↗

PLAG1-Rearranged Uterine Sarcomas: A Study of 11 Cases Showing a Wide Phenotypical Spectrum Not Limited to Myxoid Leiomyosarcoma-Like Morphology.Semantic proximity Read ↗

Inflammatory leiomyosarcoma shows frequent co-expression of smooth and skeletal muscle markers supporting a primitive myogenic phenotype: a report of 9 cases with a proposal for reclassification as low-grade inflammatory myogenic tumor.Semantic proximity Read ↗

A novel TPD52L2-ROS1 gene fusion expanding the molecular alterations in inflammatory myofibroblastic tumor: case report and literature reviewSemantic proximity Read ↗

Uterine inflammatory myofibroblastic tumors in pregnant women with and without involvement of the placenta: a study of 6 cases with identification of a novel TIMP3-RET fusion.Semantic proximity Read ↗

ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity.Semantic proximity Read ↗

Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic DifferentiationSemantic proximity Read ↗

Recent developments in uterine mesenchymal neoplasms.Semantic proximity Read ↗

Expression of Subtype-Specific Group 1 Leiomyosarcoma Markers in a Wide Variety of Sarcomas by Gene Expression Analysis and ImmunohistochemistrySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.